Treatment of Gastric and Gastroesophageal Cancer Patients with Hemodialysis by CapeOX

Two patients underwent hemodialysis. Case 1 with stage IV gastric cancer was treated with reduced doses of capecitabine (1,000 mg/m(2)/day, days 1 to 14) and oxaliplatin (65 mg/m(2), day 1). Although grade 1 thrombocytopenia occurred in the first cycle, grade 3 thrombocytopenia developed in the seco...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasaki, Kenta, Zhou, Qiliang, Matsumoto, Yoshifumi, Saiki, Takuro, Moriyama, Masato, Saijo, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815905/
https://www.ncbi.nlm.nih.gov/pubmed/31243213
http://dx.doi.org/10.2169/internalmedicine.2718-19
Descripción
Sumario:Two patients underwent hemodialysis. Case 1 with stage IV gastric cancer was treated with reduced doses of capecitabine (1,000 mg/m(2)/day, days 1 to 14) and oxaliplatin (65 mg/m(2), day 1). Although grade 1 thrombocytopenia occurred in the first cycle, grade 3 thrombocytopenia developed in the second cycle because of increasing dosage. After the dosage was reduced, chemotherapy was continued safely. Case 2 with stage IA gastroesophageal cancer was treated with radiotherapy followed by chemotherapy. Treatment with the same dose of CapeOX therapy as in case 1 resulted in no severe toxicity. We conclude that a half-dose of the CapeOX regimen is safe for gastric cancer patients undergoing hemodialysis.

Ejemplares similares